
    
      The study consisted of a Screening period of up to 4 weeks, Blinded Treatment Phase of 60
      weeks, Open-Label Continuation Period of 26 weeks, and Post-Treatment Phase of 24 weeks.

      Study Design, masking - Study treatment was blinded (double-blinded) through the Primary
      Efficacy Assessment Visit in the Blinded Treatment Period. Study treatment was open-label in
      the Open-Label Continuation Period.
    
  